Pfizer acquires Metsera for $4.9bn to expand its presence in the weight loss treatment sector. The deal includes additional payments tied to specific milestones. Metsera’s stock surged after the announcement, with Pfizer’s shares also rising. Metsera’s focus is on injectable and oral peptides for weight loss, with less frequent dosing schedules than current therapies.

Pfizer’s chief scientific officer highlighted the potential of Metsera’s portfolio to deliver value to patients and shareholders. Metsera, founded in 2022, was publicly listed earlier this year. The biotech has multiple programs in clinical trials, showing promising results for weight loss treatments. Pfizer aims to solidify its position in the obesity treatment market dominated by Novo Nordisk and Eli Lilly.

The acquisition agreement includes contingent value rights tied to specific clinical and regulatory milestones. Pfizer’s goal with the acquisition is to differentiate its pipeline in the competitive obesity treatment space. The company sees Metsera’s candidates as key revenue drivers due to their longer-lasting nature and improved dosing.

The obesity market is projected to grow significantly, creating opportunities for companies like Pfizer entering this sector. Pfizer evaluated multiple opportunities before choosing Metsera for its differentiated science and scalable platforms. Co-formulating small molecules with Metsera’s oral peptides is being considered by Pfizer for future development. This acquisition is part of Pfizer’s strategy to secure revenue streams as patent expiries for key drugs approach.

Read more at Yahoo Finance: Pfizer buys monthly GLP-1RA developer Metsera for $4.9bn